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Abstract 
 
Background: Colorectal cancer (CRC) is the second most common lethal cancer in the 
Western world. There is a 10 to 20 years lead time from normal mucosa to carcinoma 
which offers a window of opportunity to modify and prevent the outcome of CRC, with 
its incipient morbidity and mortality. 
Objective: To review the evidence for chemoprophylaxis in CRC, identify currently 
utilized agents and determine their role in the current management algorithm of CRC. 
Methods: Review of large cohort-control and randomized controlled trials in the most 
studied chemoprophylaxis agents. 
Results/conclusion: Currently, the role for chemoprophylaxis in CRC remains a niche 
area, celecoxib is the only recommended agent for utilization in patients with familial 
polyposis syndromes. However, the role of chemoprophylaxis is likely to grow 
significantly in the next decade as understanding of the stepwise tumorigenesis cascade 
becomes better understood and currently conducted clinical trials are completed.  
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1 Introduction 
 
1.1 Epidemiology 
Colorectal cancer (CRC) is the second most common lethal cancer after lung cancer 1, 
accounting for 55,000 deaths per year in the United States and its incidence is rapidly 
rising in Asia 2. Overall, the incidence of CRC in Asian countries including Hong Kong, 
Singapore, Japan and Korea is approaching that of the West 2. The detection rate of 
advanced neoplasms is between 4.5-7.8% in both Asian and Western populations. 3-6 
However, despite a declining mortality rate for CRC in the West, Asia is observing a 
rising mortality 2. Thus, CRC is a widely prevalent disease associated with considerable 
mortality and morbidity in both the East and West.  
 
The reason for the rising incidence of CRC in Asia and the high rate seen in the West is 
clearly related to a complex interplay between genetics and the environment. The 
adoption of the ‘westernized lifestyle’ which includes a diet high in fat and protein but 
low in fibre 2 is cited as a cause of CRC development. However the influence of family 
history3 and racial differences seen between different ethnic communities in Asia 
underscore the influence of genetic factors in the etiology of CRC development. In 
countries like Singapore and Malaysia where the ethnic population consists of Chinese, 
Malay and Indians, the incidence of CRC is consistently lower in Indians and Malays 
than among the Chinese 2, 4. Overall, studies in Asia have found that Japanese, Chinese 
and Koreans have a higher incidence of advanced neoplasms compared to other Asians 3, 
4. 
 
1.2 Adenoma Carcinoma Sequence 
 
Unlike lung cancer, CRC is one of the most preventable cancers, due to the long lead 
times involved in the step-wise progression from normal mucosa to adenomatous polyp 
to carcinoma, and the therapeutic interventions including colonoscopy available to 
definitively treat adenomas prior to malignant change. Polypectomies to remove 
adenomas during screening colonoscopies may lower the mortality rate from CRC by as 
much as 30-40% 5 
 
The natural evolution of normal mucosa to adenomatous polyp to overt carcinoma, spans 
on average 10-20 years 6. This long lead time presents an opportunity in terms of 
providing a window of opportunity for prevention and intervention; however it also 
complicates the study of the impact of pharmacological agents, necessitating studies of 
considerable duration and patient size to detect a significant effect. Thus as the 
epidemiology of adenomas closely resembles that of CRC itself, 7 8 prevention of 
adenomas has been used as a surrogate end-point as it is reasoned that preventing 
adenomas will most likely also prevent CRC. 
 
1.3 Risk Factors in CRC Development 
Many of the risk factors associated with CRC development including age, sex, ethnicity 
and family history are not modifiable. Older age particularly over the age of 50 is 
associated with an accelerated rate of CRC development 9, 10, hence the current 
recommendation is that CRC screening commences at the age of 50 in an average risk 
individual 11, 12. Consistently, the incidence of CRC development in males is higher than 
females 2, 9, moreover a study found that pregnancy was associated with a reduced risk of 
CRC, leading to a hypothesis that female sex hormones may be protective factor for CRC 
development 2, 13. As previously mentioned, Japanese, Korean and Chinese ethnic groups 
have a higher incidence of CRC when compared to other Asians, even when the ethnic 
population resides in the same country 4, 14, 15. Finally, a positive family history confers 
increased risk of CRC development. A prospective study showed that the age adjusted 
risk for CRC in a person with an affected first degree relative is 1.72 16. A meta-analyses 
of 27 case-control studies  found that first degree relatives of patients with CRC have an 
increased risk of colon cancer of 2.42 17and the relative risk is increased to more than 5 
fold if the index case is under 45 years 2, 18.  
 
Modifiable risk factors include obesity, smoking and ethanol intake. A meta-analyses 
found a relative risk of CRC of 1.37 for overweight and obese men 18, probable causative 
factors cited include hyper-insulinaemia and the role of oxidative stress initiated by 
hypergycaemia.9 Smoking increases the risk of CRC, more so for rectal cancers than for 
colon cancer where the risk is between 1.43-2.64 depending on the number of cigarettes 
per day 19. Ethanol intake of more than 7 standard drinks per week was associated with an 
increased risk of CRC of 1.72 , moreover the increased risk of smoking and ethanol 
intake was additive 19. Despite the plethora of detrimental health effects caused by 
obesity, smoking and excess ethanol and despite public health campaigns to raise 
awareness, the prevalence of these modifiable CRC risk factor continues to grow, with 
some even calling the global rise in obesity an epidemic.  
 
 
1.4 CRC and health seeking behaviour 
 
CRC screening via facial occult blood testing, flexible sigmoidoscopy and colonoscopy 2 
is the cornerstone of prevention. However its efficacy is limited due to low compliance 
with screening guidelines. In the United States, Canada, Europe and Australia, there is 
widespread scientific recognition of the value of CRC screening and there are national 
guidelines which support the screening program. Despite this, access to colonoscopic 
polypectomy is not yet widely available even in developed countries 20and even when 
available, the uptake of screening for CRC in those eligible remains poor 2. In Japan, only 
17% of the eligible population underwent screening 21,whereas in the West, eligible 
uptake rates were consistently less than 50% (see Table 1).  Even in patients with a 
family history of CRC, a study found that of patients with positive genetic testing 71% of 
patients had a screening colonoscopy within 12 months of diagnosis 22 In Asia, only 
several countries including Singapore, Japan, Taiwan, Korea and Australia have a 
national guideline regarding CRC screening, and overall governmental financial and 
general support for CRC is very limited. So it is not surprising the rates of screening are 
low 2. Despite the significant development of diagnostic and therapeutic tools to detect 
and treat pre-cancerous lesions in the colon and rectum, there are significant barriers to 
screening both in an average risk population and in higher risk patients, hence the need 
for the role of chemoprophylaxis in CRC to emerge. 
 
2 Aim of Chemoprophylaxis 
Chemoprophylaxis is a concept in the prevention of CRC which aims to interfere with the 
process of carcinogenesis by the targeting of key molecular pathways via pharmacologic 
agents to prevent, arrest or cause regression of adenomas, which are presumed to be 
precursors to CRC. Chemoprophylaxis can be utilized in a number of population cohorts. 
Chemoprophylaxis may be given as primary prevention, either to patients with average 
risk of CRC or only to those selected population sub-groups at higher risk of CRC, 
including relatives of patients with familial polyposis coli syndromes, or CRC. 
Chemoprophylaxis may also be utilized as secondary prevention, whereby it should be 
utilized in conjunction with CRC screening in patient sub-groups such as patients with 
detected adenomatous polyps, a prior history of CRC and family members of patients 
with CRC. The ideal chemoprophylaxis agent should be potent, inexpensive, widely 
available, and suitable to long term administration and most importantly, free from 
serious side effects.  
 2.1 Chemoprophylaxis Candidates & Mechanism of Action 
 
The 10-20 years lead time in the development of CRC provides a window during which 
chemoprophylaxis may be utilized.  However, it also complicates the studies of emergent 
pharmacologic agents, as treatment may have to be given for prolonged periods of time, 
particularly for primary prevention, before a therapeutic effect may or may not be seen. 
Moreover, large numbers of patients would need to be involved with prolonged follow-up 
which incurs problems such as escalating drop-out rates over time. Finally, studied 
patients would be subjected to additional risk involved with surveillance colonoscopies 
and polypectomies. The bulk of current evidence in chemoprophylaxis lies in studies of 
secondary prevention of either CRC or adenomas which require a shorter period of 
follow-up to assess the effect of chemoprophylaxis 23, 24.  
 
A large number of agents have been identified as potential chemoprophylaxis agents, 
predominantly from findings of observational studies. However, the results of most 
adenoma primary prevention trials have been disappointing. Studies of antioxidant 
vitamins25, fiber 26, diet 24 (median follow-up 3 years) and hormone replacement 
therapy27, conducted in average-risk populations have all been negative. The apparent 
discordance between the findings of observational studies and the concomitant 
randomized controlled studies is explainable by the fact that the former are more prone to 
confounding and bias than the latter,28 especially with regard to the assessment of 
preventive behaviors that may be difficult to detect and control for. Studies of 
chemoprophylaxis in the secondary prevention of adenomas or CRC have yielded better 
results. The best studied agents include Vitamin D and calcium, non-steroidal anti-
inflammatory drugs (NSAIDS) and cyclo-oxygenase 2 inhibitors (COX-2).  
 
2.2 Calcium & Vitamin D 
The focus on calcium and Vitamin D as possible chemoprophylaxis agents in CRC came 
from observational studies which revealed an inverse relationship between calcium and 
vitamin D intake with risk of CRC 29-32 and recurrent polyps.33, 34. The mechanisms 
underlying calcium’s  anti-carcinogenic effects in the large bowel are not clear. One 
hypothesis is based on its capability to bind to and precipitate bile acids and soluble fatty 
acids, rendering them relatively inert in the bowel lumen35, 36, whereas more recent 
studies suggest that extra cellular calcium can affect cell proliferation and differentiation 
via the calcium sensing receptor, a cell surface receptor that is expressed both in normal 
colon and colon cancer cell lines 37-39 . With regard to vitamin D, in vitro and in vivo 
studies have shown that vitamin D and vitamin D analogs can inhibit cell proliferation, 
induce differentiation, and promote apoptosis 40-42.  
 
Primary prevention of CRC through treatment with calcium and/or vitamin D has yielded 
results which generally show a reduction of CRC. 43 44 (see Table 2). A large randomized, 
double-blind, placebo-controlled trial involving over 30,000 postmenopausal women 
treated with calcium and vitamin D (dose 200IU twice daily) versus placebo for an 
average of 7.0 years found the incidence of invasive colorectal cancer did not differ 
significantly between women assigned to calcium plus vitamin D supplementation and 
those assigned to placebo, hazard ratio 1.08 (95% confidence interval (CI), 0.86 to 1.34,  
P = 0.51) 43. The ongoing 5 year extension follow-up will assess the longer-term effect of 
this intervention, as 7 years may not have been sufficient time to demonstrate the effect 
of calcium and vitamin D 43 however the longer follow-up time may or may not result in 
a different outcome as the dose of Vitamin D given to the study patients is lower than the 
dose usually utilised for CRC prevention 45. However a pooled analysis of 10 cohort 
studies, a comprehensive analysis involving 534,536 patients, assessed dietary 
consumption and total calcium intake (diet plus supplements) supported a reduction in the 
incidence of colorectal cancer of 10 to 15 percent.44, the relative risk for the highest 
versus the lowest quintile of intake was 0.86 (95% CI = 0.78 to 0.95; P(trend) =.02)  
 
More recently, two studies from Japan have found positive associations between calcium 
and/or vitamin D intake and lowering of the risk of CRC. Mizoue et al’s study found that 
the odds ratio for the highest versus the lowest quintile for calcium intake was 0.64 (95% 
confidence interval, 0.45-0.93). Higher levels of dietary vitamin D were significantly 
associated with decreased risk of colorectal cancer among those who had fewer chances 
of sunlight exposure at work or in leisure (P for trend=0.02) 46. Ishihara et al’s group 
undertook a prospective cohort study involving 74, 639 patients and found the 
multivariate hazard ratio in the highest quintile of dietary calcium intake compared with 
the lowest was 0.71 (95% CI: 0.52, 0.98) among men. No association was seen for 
Vitamin D intake 47.  
 
For secondary prevention, randomized clinical trials that found that calcium 
supplementation lowered the incidence of recurrent colorectal polyps to some degree 48, 49, 
with one report demonstrating that this protection was confined to subjects with higher 
endogenous vitamin D levels.50 
 
Previous trials demonstrating beneficial effects of calcium and/or vitamin D 
supplementation in CRC prevention, have led to the use of these agents in risk-reduction 
strategies. However, the benefits of primary prevention are mildly positive and for 
secondary prevention, the reductions have only been in the development of recurrent 
adenomas, the surrogate marker for development of CRC. 
 
5 Amino-Salicylates  
The protective association between 5-aminosalicylates (5-ASA) and CRC emerged from 
observations of patients with inflammatory bowel disease (IBD), particularly ulcerative 
colitis (UC) who were treated with 5-ASA.  The mechanism by which 5-ASA exerts its 
chemoprotective effect is unclear at present although protean mechanisms have been 
suggested. Proposed mechanisms include 5-ASA’s anti-inflammatory action on the bowel, 
action as a free-radical scavenger and it’s improvement of cellular replication fidelity 
amongst others 51 52.  
 
5-ASA has been extensively studied in the reduction of CRC only in patients with IBD, 
in particular UC. A recent meta-analysis of 9 observational studies (3 cohort, 6 case-
control) involving a total of 1,932 subjects with UC found a protective association 
between the regular use of 5-aminosalicylates and CRC (OR=0.51; 95% confidence 
interval (CI): 0.37-0.69) and a combined endpoint of CRC/dysplasia (OR 0.51; 95% CI: 
0.38-0.69) 53. A large nested case-control study involving 18,969 patients with IBD also 
supports the meta-analysis finding that regular 5-ASA usage dramatically reduced the 
risk of CRC compared to irregular usage (Adjusted OR 0.60; 95% CI 0.38-0.96)54 as do a 
number of smaller studies 55 56.  
 
Unfortunately, at present further studies are needed before 5-ASA could be recommended 
to be utilised as chemo-prophylactic agent, both in the IBD and general populace. 
Questions which will need to be answered include the optimal dose of 5-ASA, whether 
all 5-ASA are equal in their effect and finally, the role of 5-ASA when patients are 
already stabilized on an alternate agent including azathioprine 53. 
 
2.3 Non-Steroidal Anti-Inflammatory Drugs 
The suggestion of NSAIDS as possible chemoprophylaxis arose from the consistent 
concordance of data from more than 40 observational studies suggesting that NSAIDS 
reduce the incidence of colorectal adenomas, colorectal cancer, and deaths from 
colorectal cancer57. A leading hypothesis explaining the mechanism of NSAIDS in 
preventing CRC and adenomas is based on the presence of tumorigenic COX -2 within 
adenomas but not in normal intestinal tissue. COX-2 mediates the production of 
prostaglandin E2 (PGE2) in epithelial tissues, resulting in activation of signaling 
pathways that promote cell proliferation and inhibit cell death 58, 59. COX-2 is over 
expressed in 40-50% of adenomas and 85% of CRC 60.  NSAIDS, which includes 
sulindac and aspirin, the two most studied  NSAIDS as CRC chemoprophylactic agents, 
are non selective cyclo-oxygenase inhibitors (see Table 2). Emergent evidence suggest 
sulindac may exert it chemoprophylactic action via mechanisms other than via COX-2 61 
 
Sulindac, a nonselective cyclooxygenase inhibitor, was previously reported to cause 
complete or nearly complete regression of rectal adenomas in uncontrolled studies 62-65, 
and in a small, placebo-controlled, drug-crossover trial of patients with familial 
adenomatous polyposis65. Regression of rectal adenomas, though of lesser magnitude, 
was reported in two subsequent placebo-controlled studies 3.66 However, rapid recurrence 
of adenomas was observed from three months after discontinuation of drug therapy3, 65  
and evidence of long-term efficacy of sulindac is still lacking, with case reports of tumor 
progression in patients receiving sulindac67.  
 
Randomized trials of aspirin demonstrated substantial chemopreventive effect in 
secondary prevention, with reductions of approximately 20-50 percent among patients in 
whom recurrent adenomas developed.23, 68, 69 Aspirin was also associated with more 
substantial reductions in the risk of advanced lesions than in that of non-advanced lesions 
suggests that the effects of aspirin may be greater in later stages of the adenoma–
carcinoma sequence 68. These findings are tempered somewhat by the observation in one 
study that low-dose, but not high dose, aspirin had an antitumor effect68 . There was an 
increase in the risk of stroke among patients who were randomly assigned to receive 
aspirin (P=0.06), a finding consistent with previous studies of populations at low 
cardiovascular risk 68.  
 
The sulindac and aspirin studies have had generally consistent results, with benefits after 
factors including age, race, sex, and location of the tumor in the colon or the rectum have 
been controlled for, however, the gastrointestinal toxicity associated with NSAIDS at 
large may limit their long-term use for cancer prevention 70. Almost all studies indicate 
that the reduction in the risk of colorectal cancer or adenomas declines after aspirin 
therapy is stopped 71.Long-term studies, as well as direct comparisons of selective and 
nonselective cyclooxygenase inhibition, could further define the relative clinical benefits 
and adverse effects of these agents so that NSAID place in the management of CRC may 
be further clarified72 73. 
 
2.4 Cyclo-Oxygenase-2 Inhibitors 
Selective COX-2 inhibitors were developed as a safer alternative to nonselective NSAIDs, 
with respect to gastrointestinal bleeding, for the treatment of pain and inflammation. 
These agents preferentially inhibit COX-2, an inducible enzyme mediating inflammation 
and tumorigenesis, and not COX-1, the constitutively expressed enzyme responsible for 
protective mechanisms in the gastric mucosa and renal vasculature. Selective COX-2 
inhibitors have fewer effects on gastric mucosa or platelet function than do the 
nonselective NSAIDs and, as a result, may be associated with fewer ulcers and 
hemorrhagic complications 74. COX-2 inhibitors may also have effects on other enzymes, 
such as induction of 15-lipoxygenase-1 expression which could mediate its biologic 
effects 75. The best studied COX-2 inhibitors to date include celecoxib and rofecoxib (see 
Table 2).  
 
It was noted that in patients with familial adenomatous polyposis (FAP), celecoxib 
showed antitumor activity, with regression, in addition to suppression of established 
adenomas72. In a six-month study in patients with FAP, treatment with a celecoxib 
400mg twice daily was associated with statistically significant 28% regression of 
colorectal adenomas as compared to a reduction of 4.5% in the placebo group (p=0.003)72. 
Significant regression was not associated with the dose of 100 mg twice daily 72. These 
findings suggest that celecoxib could serve as an adjunct to current best management in 
the FAP syndromes by suppressing polyp formation in patients with residual rectum after 
total colectomy or in patients with an intact colon who are awaiting colectomy.  
 
Three landmark studies on COX-2 inhibitors on sporadic adenomas have demonstrated 
the significant effect of COX-2 inhibitors on secondary CRC and/or adenoma prevention. 
The Adenomatous Polyp Prevention on Vioxx (AP-PROVe) trial utilizing rofecoxib, the 
Prevention of Sporadic Adenomatous Polyps (PreSAP) trial and the Adenoma Prevention 
with Celecoxib (APC) trial both utilizing celecoxib compared to placebo, found 
statistically significant reductions in recurrent adenomas in the treatment arm over 
placebo, and moreover found that a greater effect was observed in advanced adenomas 75-
78.  
 
Tempering the significant impact of COX-2 inhibitors on the recurrence of adenomas are 
safety issues concerning COX-2 inhibitors. In both the APPROVe and APC studies there 
was a significant increase in cardiovascular events including myocardial infarction stroke, 
stroke and heart failure 76.The potential addition of COX-2 inhibitors to an optimal 
endoscopic surveillance program must be weighed against the known risk of serious 
cardiovascular events 76, 78. In the APPROVe trial a total of 46 patients in the rofecoxib 
arm had a confirmed thrombotic event compared to 26 patients in the placebo group (RR, 
1.96) 76, whilst in the APC trial, a significant dose-response excess of major 
cardiovascular events for celecoxib 200mg and 400mg of 2.5 (95% CI, 1.0-6.4) and 3.5 
(95% CI, 1.4-8.5) respectively 78, lead to premature discontinuation of both studies. 
Secondary analysis of the APC study indicates that the risk was for those patients with a 
baseline history of atherosclerotic heart disease over a median on 3.1 years 79. 
Interestingly the PreSAP trial which was also discontinued due to safety concerns did not 
find any statistically significant excess cardiovascular events in the active treatment arm 
with celecoxib 75.  
 
The studies of COX-2 are important as they demonstrate the relationship between COX-2 
and colonic adenomas. COX-2 inhibition does have a place in the secondary prevention 
of CRC. At present, given the long term safety data of COX-2 inhibitors, celecoxib is the 
only approved agent for chemoprophylaxis in high risk patients with FAP 6. 
 
3 Proof of Concept 
The place of chemoprophylaxis in CRC has been an area of interest for some time and 
provides a number of instructive points. Firstly, it demonstrates the importance of 
observational studies as flags to possible beneficial agents for prevention of CRC, but 
more importantly, this story highlights the absolute necessity to subject the findings of 
observational studies to rigorous randomized, controlled trials to determine the actual 
contribution of a proposed chemoprophylactic agent, consider anti-oxidant vitamins and 
hormone replacement therapy, whilst controlling for possible confounding factors. 
Secondly, it demonstrates the absolute necessity to demonstrate the safety of the ideal 
CRC chemoprophylaxis agent over the long term, as COX-2 inhibitors are safe over the 
short term when used as treatment for pain and inflammation and their long term safety 
issues have only come to light when utilized long term. Thirdly, the search for the ideal 
chemoprophylaxis agent has yielded a number of agents including calcium and vitamin D, 
aspirin, sulindac and celecoxib which could be used as an adjunct to currently employed 
screening methods, particularly given possibility of overlooked adenomas, since up to15- 
25 percent of small polyps may be missed in a single colonoscopy 80, 81. 5-ASA’s role as 
a chemoprophylaxis agent is at present unresolved. Finally, the search for the ideal 
chemoprophylaxis agent for CRC prevention has yielded further insight into the steps in 
tumourigenesis, mainly the proof of concept of the role of COX-2 in colonic adenoma 
development. 
 
 
4 Conclusion 
With each iteration of studies in the quest for the ideal CRC chemoprophylaxis agent, 
more knowledge is generated about CRC and the process of tumourigenesis. Although 
current chemoprophylaxis agents are imperfect, it is evident that selected patients may 
benefit from usage of calcium and vitamin D, aspirin and sulindac for secondary 
prevention of adenomas and/or CRC. In patients at high risk patients due to FAP, 
celecoxib is recommended. However, attention needs to be paid in balancing potential 
cardiovascular risk associated with COX-2 inhibitors. Newer chemoprophylaxis agents 
such as selenium, difluoromethylornithine and ursodexycholic acid 27 are on the horizon 
and are currently under investigation. Combination chemoprophylactic therapies hold 
promise to herald in a new era of reduction in the morbidity and mortality associated with 
CRC. 
 
5 Expert opinion 
The role of chemoprophylaxis in the prevention of adenomas and ultimately CRC 
continues to evolve. Current utility is in the moderate to high risk populations which 
include patients with Familial Adenomatous Polyposis Coli and Hereditary Non-
Polyposis Colorectal Cancer or Lynch’s Syndrome (see figure 1). In these patients, 
appropriate screening/surveillance remains the cornerstone of management with 
prophylactic surgery an important therapeutic adjunct. Chemoprophylaxis utilising 
celecoxib is recommended as it has been shown to arrest and possibly cause the 
regression of adenomas that develop in the interim between lower gastro-intestinal 
endoscopies. However in patients with cardio-vascular risk factors and/or history 
sulindac should be substituted for celecoxib. For patients with moderate CRC risk, the 
benefits of chemoprophylaxis must be balanced with the likely adverse effects of the 
chemoprophylactic agent. In this group with moderate risk for CRC utilization of a 
chemoprophylactic agent which is able to treat other co-morbid conditions, strengthens 
the indications for use, in particular, the utilization of calcium with or without Vitamin D 
in a patient with osteoporosis, or aspirin in a patient with concomitant cardiovascular 
disease, would deliver increased mileage for the chemoprophylactic agent whilst 
mitigating the possible adverse effects. The exception being in patients with a detected 
advanced adenoma, here it would be reasonable to administer celecoxib until the next 
surveillance colonoscopy (usually within 3 years), to treat any synchronous adenomas 
that had been missed or only partially resected. In patients with average risk of CRC, 
there are a multitude of modalities over and above chemoprophylaxis which have been 
shown to decrease the risk of CRC (see Figure 2), the most important of which are to 
manage lifestyle factors and participate in CRC screening. Here, there needs to be a 
relatively high threshold for utilizing chemoprophylaxis because of the high risk of doing 
harm.  
 
These are exciting times in the primary and secondary prevention of adenomas and CRC, 
the results from the Women’s Health Initiative and the results of the newer 
chemoprophylatic agents may change the treatment paradigm of CRC within the next 10 
years. 
 
 
Uptake of CRC Screening 
Table 1 
 
Study Country CRC Screening % Uptake * Year 
Myers et al 82 USA FOBT 41% 1993 
Hardcastle et al 
83 
United 
Kingdom 
FOBT 38.2% 1996 
Robinson et al 84 United 
Kingdom 
FOBT 37.7% 1996 
Cole et al 85 Australia FOBT 32-40.7% 2002 
Seeff et al 86 USA FOBT and/or lower 
GI endoscopy 
42.5% 2004 
Saito et al 21 Japan FOBT 17% 2006 
Zarychanski et 
al 87 
Canada FOBT and/or lower 
GI endoscopy 
17.6-23.5% 2007 
Deutekom et al 
88 
Netherlands FOBT 49% 2009 
 
* proportion of patients who take up the CRC screening when eligible to do so 
** self reported answer to questionnaire about screening for CRC 
CRC = colorectal cancer 
FOBT = Faecal occult blood testing 
 
Summary of Chemoprophylaxis Trial Outcomes  
Table 2 
 
Study Agent Type of 
Prevention*
Relative 
Risk 
Ratio 
Odds 
Ratio 
Hazard 
Ratio 
95% CI P-Value 
Wactawski-
Wende et al 43 
Calcium + 
Vitamin D 
Primary 
CRC 
  1.08 
 
0.86-
1.34 
0.51 
Baron et al 48 Calcium Secondary 
Sporadic 
0.76   0.6-
0.96  
0.02 
Bonithon-
Kopp et al 89 
Calcium Secondary 
Sporadic 
 0.66   0.3-
1.17 
0.17 
Cho et al 44 Calcium Primary  
CRC 
0.86   0.78 -
0.95 
02 
Grau et al 50 Calcium + 
Vitamin D 
Secondary 
Sporadic 
0.71**   0.57- 
0.89 
0.01 
Ishihara et al 
47 
Calcium + 
Vitamin D 
Primary 
CRC 
  0.71# 0.52 -
0.98# 
 
Mizoue et al 
46 
Calcium + 
Vitamin D 
Primary 
CRC 
0.64##   0.45-
0.93## 
 
Giardiello et 
al  3 
Sulindac FAP 0.56    0.01 
Sandler et al 
23  
Aspirin Secondary 
CRC 
0.65    0.46- 
0.91 
 
Baron et al  68 Aspirin 
81mg 
 
 
Aspirin 
325mg 
Secondary 
Sporadic 
0.81 
 
 
0.96 
  0.6-0.96 
 
0.8-1.13 
 
Benamouzig 
et al  69 
Aspirin Secondary 
Sporadic 
0.73   0.52-
1.04 
0.08 
Arber et al  75 Celecoxib Secondary 
Sporadic 
0.64   0.56- 
0.75 
<0.001 
Baron et al  77  Rofecoxib Secondary 
Sporadic 
0.76    0.69-
0.83 
< 0.0001
Bertagnolli et 
al  78 
Celecoxib 
200mg 
 
Celecoxib 
400mg 
Secondary 
Sporadic 
0.67 
 
 
0.55 
  0.59- 
0.77 
 
0.48- 
0.64 
<0.001 
 
 
<0.001 
* Refers to Primary or Secondary prevention of CRC and/or adenomas, FAP, CRC or 
sporadic denotes whether the study population was confined to patients with Familial 
Adenomatous Polyposis, prior history of Colorectal Carcinoma, or sporadic adenomas 
respectively 
** Only for patients with Vitamin D levels above the median 29.1ng/ml 
# Hazard ratio and CI refers to calcium in male study patients, no association seen 
between Vitamin D and a reduction in CRC development 
## Odds ratio and CI refers to calcium, association also seen study patients with higher 
vitamin D intake or sunlight exposure p= for trend 0.02 
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